Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance

Table 3 Univariate analysis of progression-free and overall survival

Variables		Overall survival			Progression-free survival
		HR	95%CI	P value	HR	95%CI	P value
Age (yr)	< 65/≥ 65	1.34	0.63-2.83	0.442	1.21	0.42-3.55	0.723
Sex	Male/Female	0.96	0.48-.94	0.917	0.99	0.55-1.79	0.989
IL-32 (pg/mL)	< 856.4/≥ 856.4	4.21	1.25-4.1	0.023	4.80	1.36-16.93	0.015
Creatinine (μmol/L)	< 176/≥ 176	2.11	0.50-8.88	0.308	1.1	0.08-14.67	0.941
ISS	I/II/III	1.71	1.02-2.87	0.042	1.74	1.09-2.79	0.021
DS	I/II/III	4.19	0.83-21.21	0.083	2.03	0.87-4.73	0.102
Bone disease	No/Yes	1.31	0.85-2.00	0.228	1.38	0.66-2.87	0.388
Stem cell transplantation	No/Yes	1.05	0.75-1.48	0.773	1.08	0.76-1.53	0.674
MRD	Negative/Positive	3.64	1.06-12.5	0.044	3.06	1.13-8.30	0.028

IL-32: Interleukin-32; ISS: International Staging System; DS: Durie-Salmon staging; MRD: Minimal residual disease; HR: Hazard ratio.